Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208611 · ClinicalTrials.gov registry record · Phase 2
Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00208611 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 57 participants.
The verdict
NCT00208611, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
Based on Parkinson's disease (PD)/vitamin B12 deficiency symptom overlap and PD patients' propensity to avoid protein (the dietary source of vitamin B12), this study proposes to prospectively investigate the vitamin B12 status of PD patients over time. In addition, this study will provide critical pilot data evaluating the efficacy of treating those patients considered to have below-normal vitamin B12 levels in serum. Further, it will also explore the concept that supplementing PD patients having "low-normal" vitamin B12 levels with vitamin B12 improves either the non-motor PD symptoms or homocysteine levels in PD patients receiving levodopa. Study Hypotheses: 1. Serum cobalamin (B12) concentrations in patients with Parkinson's disease (PD) are significantly lower than B12 concentrations in a) cohabiting spousal caregiver controls; and b) population-based, age-matched controls. 2. Supplementation with B12 in levodopa-treated PD patients with low (\<200 pg/ml) or low-normal (200-300 pg/ml) serum B12 levels is associated with significant improvement in their non-motor symptoms and reduces total plasma homocysteine concentration \[Hcy\], a known biomarker for risk of dementia and cerebrovascular disease.
Interventions
- DIETARY_SUPPLEMENT Vitamin B12 Supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208611
The ClinicalTrials.gov registry entry for NCT00208611 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vitamin B12 Supplementation is the first listed.
NCT00208611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00208611 about?
NCT00208611 is a clinical study titled "Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease". Based on Parkinson's disease (PD)/vitamin B12 deficiency symptom overlap and PD patients' propensity to avoid protein (the dietary source of vitamin B12), this study proposes to prospectively investigate the vitamin B12 status of PD patients over time. In addition, this study will provide critical p...
What is the current status of trial NCT00208611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2006-09. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00208611?
The interventions under investigation include: Vitamin B12 Supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00208611?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.